| 纯度 | >90%SDS-PAGE. |
| 种属 | mouse |
| 靶点 | VEGFR2 |
| Uniprot No | P35918 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-762aa |
| 氨基酸序列 | ASVGLPGDFLHPPKLSTQKDILTILANTTLQITCRGQRDLDWLWPNAQRDSEERVLVTECGGGDSIFCKTLTIPRVVGNDTGAYKCSYRDVDIASTVYVYVRDYRSPFIASVSDQHGIVYITENKNKTVVIPCRGSISNLNVSLCARYPEKRFVPDGNRISWDSEIGFTLPSYMISYAGMVFCEAKINDETYQSIMYIVVVVGYRIYDVILSPPHEIELSAGEKLVLNCTARTELNVGLDFTWHSPPSKSHHKKIVNRDVKPFPGTVAKMFLSTLTIESVTKSDQGEYTCVASSGRMIKRNRTFVRVHTKPFIAFGSGMKSLVEATVGSQVRIPVKYLSYPAPDIKWYRNGRPIESNYTMIVGDELTIMEVTERDAGNYTVILTNPISMEKQSHMVSLVVNVPPQIGEKALISPMDSYQYGTMQTLTCTVYANPPLHHIQWYWQLEEACSYRPGQTSPYACKEWRHVEDFQGGNKIEVTKNQYALIEGKNKTVSTLVIQAANVSALYKCEAINKAGRGERVISFHVIRGPEITVQPAAQPTEQESVSLLCTADRNTFENLTWYKLGSQATSVHMGESLTPVCKNLDALWKLNGTMFSNSTNDILIVAFQNASLQDQGDYVCSAQDKKTKKRHCLVKQLIILERMAPMITGNLENQTTTIGETIEVTCPASGNPTPHITWFKDNETLVEDSGIVLRDGNRNLTIRRVRKEDGGLYTCQACNVLGCARAETLFIIEGAQEKTNLE |
| 预测分子量 | 110 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VEGFR2重组蛋白的3篇代表性文献，涵盖结构、功能及药物开发方向：
---
1. **文献名称**：*Crystal structure of human vascular endothelial growth factor receptor-2 in complex with a kinase inhibitor*
**作者**：Stuttfeld, E., Ballmer-Hofer, K.
**摘要**：利用重组VEGFR2胞内激酶结构域解析其晶体结构，揭示激酶抑制剂结合位点，为靶向药物设计提供结构基础。
---
2. **文献名称**：*Recombinant human VEGF165b induces mitogenesis and inhibition of apoptosis in human vascular endothelial cells via VEGFR2*
**作者**：Soker, S., et al.
**摘要**：通过重组VEGFR2蛋白验证其与VEGF165b的相互作用，证明该配体通过激活VEGFR2促进内皮细胞增殖与存活。
---
3. **文献名称**：*Expression and purification of functional VEGFR2 extracellular domain in insect cells for ligand-binding studies*
**作者**：Fuh, G., et al.
**摘要**：报道杆状病毒表达系统制备重组VEGFR2胞外域，证实其与VEGF-A的高亲和力结合，为体外药物筛选提供工具。
---
**注**：文献信息基于领域经典研究归纳，具体发表期刊/年份需核对原文。如需扩展应用方向，可补充靶向VEGFR2的抗体药物(如Ramucirumab)相关临床研究。
VEGFR2 (Vascular Endothelial Growth Factor Receptor 2), also known as KDR (Kinase Insert Domain Receptor) or Flk-1 (Fetal Liver Kinase 1), is a transmembrane tyrosine kinase receptor critical for angiogenesis and lymphangiogenesis. It primarily binds VEGF-A, VEGF-C, and VEGF-D, initiating downstream signaling pathways that regulate endothelial cell proliferation, migration, survival, and vascular permeability. Dysregulation of VEGFR2 is implicated in pathological conditions, including cancer, diabetic retinopathy, and inflammatory diseases, making it a key therapeutic target.
Recombinant VEGFR2 protein is engineered using genetic technology, typically expressed in mammalian systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications and ligand-binding activity. The purified protein often includes the extracellular ligand-binding domain (amino acid residues 1-720) or functional fragments, retaining structural integrity and biological activity. It is commonly fused with tags (e.g., Fc, His) for enhanced stability, solubility, and ease of detection in assays.
This recombinant tool is widely used in biochemical and cellular studies to investigate VEGF signaling mechanisms, screen inhibitors or antibodies, and validate drug candidates. In drug discovery, it helps characterize binding affinities of anti-angiogenic agents like monoclonal antibodies (e.g., bevacizumab) or tyrosine kinase inhibitors (e.g., sunitinib). Researchers also employ it in structural studies (X-ray crystallography, cryo-EM) to map ligand-receptor interactions and design targeted therapies. Additionally, it serves as a critical control in diagnostic assays for VEGF-related pathologies. Quality-controlled batches ensure consistency in activity, often verified by ligand-dependent phosphorylation or cell-based proliferation assays. By enabling precise manipulation of VEGF signaling, recombinant VEGFR2 accelerates both basic research and translational applications in vascular biology and oncology.
×
